Andrea Lopes Ponte de Souza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea Lopes Ponte de Souza has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Adilio Roberto Bernardes
2 shared publicationsAline Almeida Goncalves Mariano
2 shared publications- Bruna dos Santos Sampaio
Hospital Israelita Albert Einstein, São Paulo, Brazil
2 shared publications Camila Santos Nascimento de Albuquerque
2 shared publications- Diogo Diniz Gomes Bugano
Hospital Israelita Albert Einstein, São Paulo, Brazil
2 shared publications Diogo Duarte Fagundes Moia
Hospital Israelita Albert Einstein, São Paulo, Brazil
2 shared publications
Latest Publications
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2500526
Real-World Epidemiology, Treatment Patterns, and Outcomes of Hepatocellular Carcinoma in Brazil: A Multicenter Retrospective Study
The treatment landscape of hepatocellular carcinoma (HCC) has evolved substantially; however, limited access to novel therapies and regional epidemiologic differences lead to heterogeneous real-world treatment patterns worldwide. The purpose of this study was to describe the epidemiology, treatment patterns, and outcomes of patients diagnosed with HCC in Brazil between 2017 and 2022. This was a national, multicenter, retrospective, real-world observational study including patients with confirmed HCC and first diagnosis between 2017 and 2022. Data were collected from 10 centers across four geographic regions in Brazil. Of 318 patients screened, 303 were included: 107 with early-stage disease Barcelona Clinic Liver Cancer (BCLC 0-B) and 196 with advanced-stage disease (BCLC C-D). The median age was 71 years (64-77); 77.6% were men, 48.5% self-identified as Black or mixed race, and 62% were treated in public institutions. Main etiologies were hepatitis C virus (35%), alcohol-related liver disease (27.4%), hepatitis B virus (7.6%), and metabolic dysfunction-associated steatotic liver disease (MASLD; 10.9%). Among early-stage patients, 57% was classified as Child-Pugh A and 85% received local therapy (26.7% surgery or ablation; 58.8% transarterial chemoembolization [TACE]/Drug-Eluting Bead-TACE). The median progression-free survival was 10.4 months (95% CI, 8.7 to 15.7), and the median overall survival (OS) was 19.6 months (95% CI, 15.9 to 29.0). In advanced disease, 41% was classified as Child-Pugh A, portal vein thrombosis was present in 39.8%, and extrahepatic disease was present in 42.9%. Systemic therapy was administered to 48.5% of patients. The median OS was 8 months with systemic therapy versus 3 months without treatment. In this Brazilian real-world cohort, hepatitis C and alcohol were the predominant etiologies, whereas MASLD accounted for 10% of cases. Although most localized cases received locoregional therapy with outcomes consistent with the literature, access to modern systemic treatments for advanced disease remained limited.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2500526
Real-World Epidemiology, Treatment Patterns, and Outcomes of Hepatocellular Carcinoma in Brazil: A Multicenter Retrospective Study
The treatment landscape of hepatocellular carcinoma (HCC) has evolved substantially; however, limited access to novel therapies and regional epidemiologic differences lead to heterogeneous real-world treatment patterns worldwide. The purpose of this study was to describe the epidemiology, treatment patterns, and outcomes of patients diagnosed with HCC in Brazil between 2017 and 2022. This was a national, multicenter, retrospective, real-world observational study including patients with confirmed HCC and first diagnosis between 2017 and 2022. Data were collected from 10 centers across four geographic regions in Brazil. Of 318 patients screened, 303 were included: 107 with early-stage disease Barcelona Clinic Liver Cancer (BCLC 0-B) and 196 with advanced-stage disease (BCLC C-D). The median age was 71 years (64-77); 77.6% were men, 48.5% self-identified as Black or mixed race, and 62% were treated in public institutions. Main etiologies were hepatitis C virus (35%), alcohol-related liver disease (27.4%), hepatitis B virus (7.6%), and metabolic dysfunction-associated steatotic liver disease (MASLD; 10.9%). Among early-stage patients, 57% was classified as Child-Pugh A and 85% received local therapy (26.7% surgery or ablation; 58.8% transarterial chemoembolization [TACE]/Drug-Eluting Bead-TACE). The median progression-free survival was 10.4 months (95% CI, 8.7 to 15.7), and the median overall survival (OS) was 19.6 months (95% CI, 15.9 to 29.0). In advanced disease, 41% was classified as Child-Pugh A, portal vein thrombosis was present in 39.8%, and extrahepatic disease was present in 42.9%. Systemic therapy was administered to 48.5% of patients. The median OS was 8 months with systemic therapy versus 3 months without treatment. In this Brazilian real-world cohort, hepatitis C and alcohol were the predominant etiologies, whereas MASLD accounted for 10% of cases. Although most localized cases received locoregional therapy with outcomes consistent with the literature, access to modern systemic treatments for advanced disease remained limited.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (4) , e2500324
Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study
PURPOSE: Disparities in health care access and resource availability in middle-income countries often lead to suboptimal management of localized bladder urothelial carcinoma (UC). However, real-world data describing treatment patterns and outcomes in these settings remain limited. METHODS: This multicenter, retrospective, real-world study included patients with high-risk non–muscle-invasive (HR-NMIBC) and localized muscle-invasive bladder cancer (MIBC) diagnosed between 2017 and 2022 across nine cancer centers in a middle-income setting. Treatment data and clinical outcomes were collected from medical records and analyzed using descriptive statistics and Kaplan-Meier survival estimates. RESULTS: Among 343 patients analyzed, 217 (63.3%) had HR-NMIBC, of whom only 29.5% received adjuvant Bacillus Calmette-Guérin (BCG), often substituted with intravesical gemcitabine because of supply shortages. BCG exposure was associated with superior overall and cancer-specific survival compared with non-BCG patients. In the muscle-invasive cohort (n = 126; 36.7%), cystectomy was performed in 48.4% and significantly improved survival. Perioperative chemotherapy remained limited, with only 39.3% receiving neoadjuvant therapy, and just one third receiving cisplatin-based regimens that conferred the greatest survival benefit. CONCLUSION: This multicenter real-world study exposes major gaps in the management of localized UC in a middle-income setting. Limited access to BCG, perioperative chemotherapy, and cystectomy remain key barriers to guideline-concordant care, underscoring the urgent need for policy actions to improve treatment delivery and outcomes in comparable health care systems.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (4) , e2500324
Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study
PURPOSE: Disparities in health care access and resource availability in middle-income countries often lead to suboptimal management of localized bladder urothelial carcinoma (UC). However, real-world data describing treatment patterns and outcomes in these settings remain limited. METHODS: This multicenter, retrospective, real-world study included patients with high-risk non–muscle-invasive (HR-NMIBC) and localized muscle-invasive bladder cancer (MIBC) diagnosed between 2017 and 2022 across nine cancer centers in a middle-income setting. Treatment data and clinical outcomes were collected from medical records and analyzed using descriptive statistics and Kaplan-Meier survival estimates. RESULTS: Among 343 patients analyzed, 217 (63.3%) had HR-NMIBC, of whom only 29.5% received adjuvant Bacillus Calmette-Guérin (BCG), often substituted with intravesical gemcitabine because of supply shortages. BCG exposure was associated with superior overall and cancer-specific survival compared with non-BCG patients. In the muscle-invasive cohort (n = 126; 36.7%), cystectomy was performed in 48.4% and significantly improved survival. Perioperative chemotherapy remained limited, with only 39.3% receiving neoadjuvant therapy, and just one third receiving cisplatin-based regimens that conferred the greatest survival benefit. CONCLUSION: This multicenter real-world study exposes major gaps in the management of localized UC in a middle-income setting. Limited access to BCG, perioperative chemotherapy, and cystectomy remain key barriers to guideline-concordant care, underscoring the urgent need for policy actions to improve treatment delivery and outcomes in comparable health care systems.